“It has been 25 years since a new drug was approved for the treatment of neuropsychiatric disorders,” according to Chicca, who serves as chief executive of the biotech. We have also made significant progress on the clinical front and recently engaged Worldwide Clinical Trials as the contract research organization, Image Analysis Group ("IAG") as the imaging partner, and Berry Consultants as a biostatistical advisor for our Phase 2 trial design. It has also received funding from the European Commission to develop SYT-510 as a treatment for post-traumatic stress disorder. Phase 2 trial for Berubicin in Q1 of 2021 and we continue to demonstrate our ability to execute our operational and clinical plans toward that goal.". The FDA recently granted the Company Orphan Drug Designation (ODD) for Berubicin for the treatment of malignant gliomas, which include GBM. The company was founded as a spin-off of the University of Bern and Swiss research institute NCCR TransCure in April 2019, and is focused on the development of a new class of drugs that work on endocannabinoids, a type of neurotransmitter that bind to the receptors in the brain targeted by cannabinoid compounds. Under this dual-track strategy, it engaged two separate manufacturers for Berubicin on different continents, both U.S.-based Pharmaceutics International, Inc. ("Pii") and Italy-based BSP. Forward-looking statements in this press release include, without limitation, the ability of the Company to file an IND in the fourth quarter of this year and to initiate its Phase 2 trial for Berubicin in the first quarter of 2021. Website and content copyright © 2009-, pharmaphorum media limited or its licensors; Another is Corbus Therapeutics of the US, although its interest is mainly in drugs for inflammatory and fibrotic diseases rather than CNS. Along with SYT-510, the company has identified two other backup compounds from a screening process that started with more than 12 million candidates. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. "With the manufacturing of our Berubicin Drug Product in Europe, we continue to advance closer toward an IND filing for Berubicin, which we expect to submit later this quarter. They are the original manufacturer of Tissue-Tek® products that have become industry standards over the years. Synendos isn’t the only company exploring the potential of the endocannabinoid system. View original content to download multimedia:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-begins-manufacturing-of-berubicin-in-europe-301149177.html, © 1985 - 2020 BioSpace.com. The rights of trade mark owners are acknowledged. Powered by Madgex Job Board Software, http://www.prnewswire.com/news-releases/cns-pharmaceuticals-begins-manufacturing-of-berubicin-in-europe-301149177.html. Terminvereinbarung in unseren Zweigstellen. The Basel-based biotech – which was incubated in Switzerland’s BaseLaunch accelerator – is concentrating on developing a new class of small-molecule drugs for anxiety, mood and stress-related disorders. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value. Euro-CNS aims to promote and maintain the harmonisation of neuropathology training and clinical practice throughout Europe, and to promote the science of neuropathology and neuropathology research. Our laser focus remains on initiating a U.S. BIO-Europe Digital comes at a time when global connections are more important than ever.